Concomitant Administration of Different Doses of Simvastatin with Ivabradine Influence on PAI-1 and Heart Rate in Normo- and Hypercholesterolaemic Rats

Table 1

Total cholesterol (TCH), HDL-cholesterol, LDL-cholesterol, and triglycerides (TGs) (mean ± SD) in rats fed normocholesterolaemic diet (mmol/l).

	TCH	HDL	LDL	TGs
K_N (𝑛=10)	1,48 ± 0,12	0,38 ± 0,09	0,95 ± 0,29	0,32 ± 0,13
IW_N (𝑛=9)	1,11 ± 0,03	0,34 ± 0,08	0,65 ± 0,17	0,25 ± 0,08
S1_N (𝑛=10)	1,34 ± 0,21	0,57 ± 0,05*	0,56 ± 0,14*	0,46 ± 0,14
S20_N (𝑛=7)	1,39 ± 0,14	0,69 ± 0,14*	0,44 ± 0,09*	0,56 ± 0,18
IW_N_S1 (𝑛=6)	1,53 ± 0,14	0,64 ± 0,15*	0,61 ± 0,09*	0,62 ± 0,26
IW_N_S20 (𝑛=8)	1,37 ± 0,12	0,56 ± 0,18*	0,59 ± 0,10*	0,48 ± 0,15

K_N: normocholesterolaemic control group, IW_N: normocholesterolaemic group receiving ivabradine, S1_N: normocholesterolaemic group receiving simvastatin at a dose of 1 mg × kg⁻¹ bw, S20_N: normocholesterolaemic group receiving simvastatin at a dose of 20 mg × kg⁻¹bw, IW_N_S1: normocholesterolaemic group receiving ivabradine and simvastatin at a dose of 1 mg × kg⁻¹bw, IW_N_S20: normocholesterolaemic group receiving ivabradine and simvastatin at a dose of 20 mg × kg⁻¹bw ^∗𝑃<0.05 as compared to the control group.